Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up
Parkinson's disease (PD) is a progressive neurodegenerative disorder, and the rate of progression is different across individuals. Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to produce long-term symptom improvement in PD. In this retrospective study, we wanted to explor...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00600/full |
id |
doaj-1e1c736c2505453c834806c73cd14772 |
---|---|
record_format |
Article |
spelling |
doaj-1e1c736c2505453c834806c73cd147722020-11-25T03:00:32ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-07-011110.3389/fneur.2020.00600536588Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-UpRenli QiXin GengBaihui HuangYe ChenHonggao JiangYanghong ZouWei WangYubin LiYushan LiLei YinAnxiong LiuXuelan YangJinghui LiHualin YuParkinson's disease (PD) is a progressive neurodegenerative disorder, and the rate of progression is different across individuals. Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to produce long-term symptom improvement in PD. In this retrospective study, we wanted to explore the effects of bilateral STN-DBS in PD patients with different rates of disease progression. Forty patients with PD were included. An index of progression rate was calculated by the ratio of the Unified Parkinson Disease Rating Scale, part III (UPDRS-III), score in the off-medication condition at baseline and disease duration. The patients were divided into fast-, medium-, and slow-progression groups by this index. The outcome measurements at the 1st, 6th, and 12th months after surgery were the changes in UPDRS-III scores in the off-medication/on-stimulation condition compared with the baseline. We found the following. (1). Motor functions in the different PD progression groups were improved by bilateral STN-DBS treatment at 1 year of follow-up. (2). However, compared to the slow- and medium-progression groups, the fast-progression group had less improvement at the 6th- and 12th-month follow-up. The results indicated that bilateral STN-DBS can improve motor functions of Parkinson's patients over the 1-year follow-up. Moreover, the outcomes in the slow- and medium-progression patients were better than those with fast-progression rates.https://www.frontiersin.org/article/10.3389/fneur.2020.00600/fullParkinson's diseasedeep brain stimulationsubthalamic nucleusdisease progressionoutcome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Renli Qi Xin Geng Baihui Huang Ye Chen Honggao Jiang Yanghong Zou Wei Wang Yubin Li Yushan Li Lei Yin Anxiong Liu Xuelan Yang Jinghui Li Hualin Yu |
spellingShingle |
Renli Qi Xin Geng Baihui Huang Ye Chen Honggao Jiang Yanghong Zou Wei Wang Yubin Li Yushan Li Lei Yin Anxiong Liu Xuelan Yang Jinghui Li Hualin Yu Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up Frontiers in Neurology Parkinson's disease deep brain stimulation subthalamic nucleus disease progression outcome |
author_facet |
Renli Qi Xin Geng Baihui Huang Ye Chen Honggao Jiang Yanghong Zou Wei Wang Yubin Li Yushan Li Lei Yin Anxiong Liu Xuelan Yang Jinghui Li Hualin Yu |
author_sort |
Renli Qi |
title |
Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up |
title_short |
Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up |
title_full |
Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up |
title_fullStr |
Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up |
title_full_unstemmed |
Outcomes of STN-DBS in PD Patients With Different Rates of Disease Progression Over One Year of Follow-Up |
title_sort |
outcomes of stn-dbs in pd patients with different rates of disease progression over one year of follow-up |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2020-07-01 |
description |
Parkinson's disease (PD) is a progressive neurodegenerative disorder, and the rate of progression is different across individuals. Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to produce long-term symptom improvement in PD. In this retrospective study, we wanted to explore the effects of bilateral STN-DBS in PD patients with different rates of disease progression. Forty patients with PD were included. An index of progression rate was calculated by the ratio of the Unified Parkinson Disease Rating Scale, part III (UPDRS-III), score in the off-medication condition at baseline and disease duration. The patients were divided into fast-, medium-, and slow-progression groups by this index. The outcome measurements at the 1st, 6th, and 12th months after surgery were the changes in UPDRS-III scores in the off-medication/on-stimulation condition compared with the baseline. We found the following. (1). Motor functions in the different PD progression groups were improved by bilateral STN-DBS treatment at 1 year of follow-up. (2). However, compared to the slow- and medium-progression groups, the fast-progression group had less improvement at the 6th- and 12th-month follow-up. The results indicated that bilateral STN-DBS can improve motor functions of Parkinson's patients over the 1-year follow-up. Moreover, the outcomes in the slow- and medium-progression patients were better than those with fast-progression rates. |
topic |
Parkinson's disease deep brain stimulation subthalamic nucleus disease progression outcome |
url |
https://www.frontiersin.org/article/10.3389/fneur.2020.00600/full |
work_keys_str_mv |
AT renliqi outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT xingeng outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT baihuihuang outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT yechen outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT honggaojiang outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT yanghongzou outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT weiwang outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT yubinli outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT yushanli outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT leiyin outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT anxiongliu outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT xuelanyang outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT jinghuili outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup AT hualinyu outcomesofstndbsinpdpatientswithdifferentratesofdiseaseprogressionoveroneyearoffollowup |
_version_ |
1724697523353812992 |